C57BL/6NCya-Eif2ak2em1/Cya
Common Name
Eif2ak2-KO
Product ID
S-KO-03784
Backgroud
C57BL/6NCya
Strain ID
KOCMP-19106-Eif2ak2-B6N-VA
Status
When using this mouse strain in a publication, please cite “Eif2ak2-KO Mouse (Catalog S-KO-03784) were purchased from Cyagen.”
Product Type
Age
Genotype
Sex
Quantity
The standard delivery applies for a guaranteed minimum of three heterozygous carriers. Breeding services for homozygous carriers and/or specified sex are available.
Basic Information
Strain Name
Eif2ak2-KO
Strain ID
KOCMP-19106-Eif2ak2-B6N-VA
Gene Name
Product ID
S-KO-03784
Gene Alias
Pkr, Tik, Prkr, 2310047A08Rik, 4732414G15Rik
Background
C57BL/6NCya
NCBI ID
Modification
Conventional knockout
Chromosome
Chr 17
Phenotype
Datasheet
Application
--
Strain Description
Ensembl Number
ENSMUST00000024884
NCBI RefSeq
NM_011163
Target Region
Exon 3
Size of Effective Region
~0.1 kb
Overview of Gene Research
Eif2ak2, also known as protein kinase R (PKR), is a kinase that phosphorylates eukaryotic translation initiation factor 2 alpha (eIF2α), orchestrating the cellular stress response [4]. It is involved in multiple pathways, including endoplasmic reticulum stress response [3], and has been linked to the regulation of immune response and histone protein gene transcription, especially in relation to systemic lupus erythematosus [5].
In Eif2ak2 gene knockdown mice, the inhibitory effect of berberine on the secretion of inflammatory cytokines (IL-1β, IL-6, IL-18, and TNF-α) was significantly attenuated, demonstrating an Eif2ak2-dependent anti-inflammatory efficacy [1]. Also, Eif2ak2 depletion in in vitro models using LPS-stimulated HK2 cells showed reduced PANoptosis, indicating its role in sepsis-induced acute kidney injury through promoting AIM2-mediated PANoptosis [2].
In conclusion, Eif2ak2 is crucial for the cellular stress response and plays a significant role in inflammation-related disorders and sepsis-induced acute kidney injury. The gene knockdown mouse models have been instrumental in revealing its functions in these disease conditions, providing insights into potential therapeutic strategies for these diseases.
References:
1. Wei, Wei, Zeng, Qingxuan, Wang, Yan, Jiang, Jiandong, Song, Danqing. 2022. Discovery and identification of EIF2AK2 as a direct key target of berberine for anti-inflammatory effects. In Acta pharmaceutica Sinica. B, 13, 2138-2151. doi:10.1016/j.apsb.2022.12.009. https://pubmed.ncbi.nlm.nih.gov/37250154/
2. Wei, Siwei, Wu, Lei, Xiang, Zhen, Jiang, Liubing, Du, Zhen. 2024. EIF2AK2 protein targeted activation of AIM2-mediated PANoptosis promotes sepsis-induced acute kidney injury. In Renal failure, 46, 2403649. doi:10.1080/0886022X.2024.2403649. https://pubmed.ncbi.nlm.nih.gov/39311631/
3. Thomsen, Mirja, Lange, Lara M, Zech, Michael, Lohmann, Katja. 2023. Genetics and Pathogenesis of Dystonia. In Annual review of pathology, 19, 99-131. doi:10.1146/annurev-pathmechdis-051122-110756. https://pubmed.ncbi.nlm.nih.gov/37738511/
4. Kuipers, Demy J S, Mandemakers, Wim, Lu, Chin-Song, Bertoli-Avella, Aida M, Bonifati, Vincenzo. 2020. EIF2AK2 Missense Variants Associated with Early Onset Generalized Dystonia. In Annals of neurology, 89, 485-497. doi:10.1002/ana.25973. https://pubmed.ncbi.nlm.nih.gov/33236446/
5. Ge, Lan, Zhang, Yuhong, Zhao, Xingwang, Zhang, Yi, You, Yi. 2021. EIF2AK2 selectively regulates the gene transcription in immune response and histones associated with systemic lupus erythematosus. In Molecular immunology, 132, 132-141. doi:10.1016/j.molimm.2021.01.030. https://pubmed.ncbi.nlm.nih.gov/33588244/
Quality Control Standard
Sperm Test
Pre-cryopreservation: Measurement of sperm concentration, determination of sperm viability.
Post-cryopreservation: A vial of cryopreserved sperms is selected for in-vitro fertilization from each batch.
Environmental Standards:SPF
Available Region:Global
Source:Cyagen
Contact Us
Connect with our experts for your custom animal model needs. Please fill out the form below to start a conversation or request a quote.
Cyagen values your privacy. We’d like to keep you informed about our latest offerings and insights. Your preferences:
You may unsubscribe from these communications at any time. See our Privacy Policy for details on opting out and data protection.
By clicking the button below, you consent to allow Cyagen to store and process the personal information submitted in this form to provide you the content requested.
